We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As sales of its blockbuster asthma and COPD drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from its other products. Turns out diabetes was the key.